Table 1: Rhabdomyolysis,
myopathy and increased CPK reactions associated with statins as reported
to the CADRMP from date marketed in Canada to Aug. 24, 2001*
Drug and year marketed in Canada; no. of reports
| Reaction† |
Atorvastatin
1997
|
Cerivastatin
1998
|
Fluvastatin
1994
|
Lovastatin
1988
|
Pravastatin
1990
|
Simvastatin
1990
|
|
| Rhabdomyolysis |
10
|
54
|
-
|
12
|
3
|
7
|
| |
|
|
|
|
|
|
| Myopathy‡ |
32
|
8
|
5
|
24
|
17
|
34
|
| |
|
|
|
|
|
|
CPK increased
with
myopathy‡ |
16
|
11
|
1
|
6
|
4
|
6
|
| |
|
|
|
|
|
|
CPK increased
without
myopathy‡ |
5
|
6
|
-
|
4
|
6
|
5
|
|
Total
no. of
reports received |
231
|
121
|
43
|
182
|
123
|
170
|
Note:
CPK = creatine phosphokinase, CADRMP = Canadian Adverse Drug Reaction Monitoring
Program.
*
These data cannot be used to determine the incidence of adverse drug reactions
because neither patient exposure nor the amount of time the drug was on
the market has been taken into consideration. See caveat at the end of
the newsletter.
Each
report may contain more than 1 of these reactions; however, reports were
only included in the most significant category.
‡
Myopathy may include muscle symptoms such as myositis, myalgia, muscle
ache, muscle weakness, muscle cramp, muscle discomfort.
|
